BioSpace News Archive

The U.S. government is putting together the infrastructure for widespread distribution of a COVID-19 vaccine, if and when one is granted emergency use authorization (EUA) or full approval.

Results from a Phase III open-label extension trial showed that the safety and efficacy profile observed in previous Dupixent trials were maintained for up to three years in adults and adolescents with moderate-to-severe asthma.

The portfolio is made up of well-established injectable coagulants sold in Europe under various brand names, including Arixtra, Fraxiparine, Mon-Embolex and Orgaran.

Lenabasum is an oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2).

The transaction, which is set to conclude in early 2021, will give Grifols access to Alkahest’s four product candidates.

The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.

For patients with epilepsy, the diagnosis and treatment process can be long, arduous, and filled with lengthy hospital stays. The medical device company NeuroOne Medical Technologies Corporation hopes to change that.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that the Company has been awarded a new research & development grant for 2020 of up to 1.95 million Israeli New Shekels (approximately $573,000) from the Israel Innovation Authority (IIA). The grant, which is one of the first under the IIA

BioTalent Canada announced today preliminary findings from its most recent bio-economy Labour Market Information (LMI) study.